Curcumin Derivatives for Brain-Penetrant Tau Oligomer Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Curcumin's low cerebral bioavailability hampers its use as a therapeutic agent for Alzheimer's disease and related neurodegenerative disorders due to rapid metabolism and poor solubility, limiting its effectiveness in targeting and modulating tau oligomers.
Innovation Solution
Synthesis of novel curcumin derivatives, including Hemi-curcuminoids, Curcumin-like, Heterocyclic curcumin-like, and Calebin-A analogs, designed to easily cross the blood-brain barrier and modulate tau oligomers' aggregation state, neutralizing their toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is used to target tau oligomers, then it can bind and modulate tau aggregation, but its low cerebral bioavailability and rapid metabolism limit its effectiveness
Solution Approach 1:
The patent modifies curcumin's chemical structure by creating derivatives with altered parameters (molecular weight, lipophilicity, metabolic stability) to improve brain penetration and reduce rapid metabolism while retaining tau-binding capability
Solution Approach 2:
The patent develops composite formulations including liposomal encapsulation and nanoparticle systems that combine curcumin with carrier materials to enhance stability, solubility, and cerebral delivery efficiency
2Quantity of substance
If curcumin is administered orally, then it can reach systemic circulation, but poor solubility in aqueous buffers reduces its bioavailability
Solution Approach 1:
The patent employs liposomal vesicles with flexible phospholipid membranes that encapsulate curcumin, protecting it from degradation and enhancing its solubility in aqueous environments while facilitating cellular uptake
Solution Approach 2:
The patent utilizes nanoporous carrier materials with controlled pore sizes that enhance curcumin dissolution and provide sustained release profiles, improving overall bioavailability
3Reliability
If curcumin is used to suppress tau oligomers, then it can reduce tau pathology, but rapid glucuronidation metabolism prevents sufficient accumulation in the brain
Solution Approach 1:
The patent designs curcumin derivatives with modified metabolic parameters, specifically reducing glucuronidation susceptibility through structural modifications that extend half-life and improve brain residence time
Solution Approach 2:
The patent introduces metabolic stabilizers and enzyme inhibitors as intermediary substances that protect curcumin from rapid glucuronidation, allowing sufficient accumulation in the brain to achieve therapeutic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The curcumin derivatives effectively decrease tau oligomer levels and protect neurons from toxicity, promoting the formation of larger, non-toxic aggregates, while maintaining cell viability.
Implementation Method 1
small molecules that bind and/or modulate different forms of tau oligomers
Data Source
AI summary
The present invention relates to novel small molecules of Formulas I, II, III, Illa, IlIb, and IV and pharmaceutically acceptable salts thereof, as well as the preparation and the use thereof.